ARTICLE | Company News
Biogen opts in for Ionis' ALS candidate, plans pivotal trial
December 7, 2018 6:15 PM UTC
Biogen Inc. (NASDAQ:BIIB) exercised its option for exclusive, worldwide rights to BIIB067 (IONIS-SOD1Rx) from Ionis Pharmaceuticals Inc. (NASDAQ:IONS) to treat amyotrophic lateral sclerosis with superoxide dismutase 1 (SOD1) mutations.
Biogen, which opted in after seeing interim Phase I data, plans to begin a pivotal trial of the SOD1-inhibiting antisense oligonucleotide. Biogen declined to give a timeline...
BCIQ Target Profiles